Luke: Difference between revisions
From MalariaETC
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
< | <h2>PML::RARA – Low Risk APL</h2> | ||
<table> | |||
<tr> | |||
<th>Gene</th> | |||
<th>Timepoints – on treatment</th> | |||
<th>Duration</th> | |||
<th>Follow-up post therapy</th> | |||
<th>Notes</th> | |||
</tr> | |||
<tr> | |||
<td>PML::RARA</td> | |||
<td>Bone marrow MRD – post each cycle of treatment</td> | |||
<td>Stop performing MRD once CRMRD</td> | |||
<td></td> | |||
<td>Recommended by both ELN and Dillon et al</td> | |||
</tr> | |||
</table> | |||
<h2>PML::RARA – High Risk APL</h2> | |||
<table> | |||
<tr> | |||
<th>Gene</th> | |||
<th>Timepoints – on treatment</th> | |||
<th>Duration</th> | |||
<th>Follow-up post therapy</th> | |||
<th>Notes</th> | |||
</tr> | |||
<tr> | |||
<td>PML::RARA</td> | |||
<td>Bone marrow MRD – post each cycle of treatment</td> | |||
<td></td> | |||
<td>BM MRD every 3 months for 2–3 years</td> | |||
<td> | |||
Recommended by both ELN and Dillon et al<br> | |||
ELN recommend 2 years | |||
</td> | |||
</tr> | |||
</table> | |||
<h2>NPM1</h2> | |||
<table> | |||
<tr> | |||
<th>Gene</th> | |||
<th>Timepoints – on treatment</th> | |||
<th>Additional tests</th> | |||
<th>Follow-up post therapy</th> | |||
<th>Notes</th> | |||
</tr> | |||
<tr> | |||
<td>NPM1</td> | |||
<td>Bone marrow MRD – post each cycle of treatment</td> | |||
<td>PB MRD sample post cycle 2</td> | |||
<td> | |||
BM 3 monthly for 2 years<br> | |||
PB 2 monthly for 2 years | |||
</td> | |||
<td> | |||
Post #2 PB sample based on AML 17 and Dillon et al<br> | |||
*Recommendations based on Dillon et al.<br> | |||
ELN recommends PB monitoring 4–6 weekly | |||
</td> | |||
</tr> | |||
</table> | |||
Revision as of 10:21, 31 July 2025
PML::RARA – Low Risk APL
| Gene | Timepoints – on treatment | Duration | Follow-up post therapy | Notes |
|---|---|---|---|---|
| PML::RARA | Bone marrow MRD – post each cycle of treatment | Stop performing MRD once CRMRD | Recommended by both ELN and Dillon et al |
PML::RARA – High Risk APL
| Gene | Timepoints – on treatment | Duration | Follow-up post therapy | Notes |
|---|---|---|---|---|
| PML::RARA | Bone marrow MRD – post each cycle of treatment | BM MRD every 3 months for 2–3 years |
Recommended by both ELN and Dillon et al |
NPM1
| Gene | Timepoints – on treatment | Additional tests | Follow-up post therapy | Notes |
|---|---|---|---|---|
| NPM1 | Bone marrow MRD – post each cycle of treatment | PB MRD sample post cycle 2 |
BM 3 monthly for 2 years |
Post #2 PB sample based on AML 17 and Dillon et al |